People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?-Reference-Cited by-同舟云学术

People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

Published:2024-02-01 Issue:3 Volume:38 Page:430-434
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Bartalucci Claudia¹²,Baldi Federico¹²,Ricci Elena³,Orofino Giancarlo⁴,Menzaghi Barbara⁵,Ferrara Sergio⁶,Pellicano’ Giovanni Francesco⁷,Squillace Nicola⁸,Sarchi Eleonora⁹,Pontali Emanuele¹⁰,Cenderello Giovanni¹¹,Bargiacchi Olivia¹²,Piccica Matteo¹³,Carleo Maria Aurora¹⁴,Cascio Antonio¹⁵,De Socio Giuseppe Vittorio¹⁶,Bonfanti Paolo⁸¹⁷,Di Biagio Antonio¹²

Affiliation:

1. DISSAL, University of Genova

2. IRCCS Ospedale Policlinico San Martino, Genova

3. Fondazione ASIA Onlus, Buccinasco (MI)

4. Division I of Infectious and Tropical Diseases, ASL Città di Torino

5. Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA)

6. S.C. Malattie Infettive Universitarie AOU OO.RR., Foggia

7. Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age ‘G. Barresi’, University of Messina, Messina

8. Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza

9. Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria

10. Department of Infectious Diseases, Galliera Hospital, Genoa

11. SC Malattie Infettive, ASL1 Imperiese, Sanremo

12. Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara

13. SOC 1 USLCENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence

14. Infectious Diseases and Gender Medicine Unit, PO Cotugno, AO dei Colli, Napoli

15. Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

16. Unit of Infectious Diseases, Santa Maria Hospital, Perugia

17. University of Milano-Bicocca, Italy.

Abstract

Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference17 articles.

1. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection;Thoueille;J Antimicrob Chemother,2022

2. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression;Swindells;N Engl J Med,2020

3. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study;Overton;Lancet,2020

4. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study;Orkin;Lancet HIV,2021

5. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial;Margolis;Lancet,2017